Skip to main content

Abeona Therapeutics Inc.

ABEO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000318306

In the last 90 days, Abeona Therapeutics Inc. insiders filed 0 open-market purchases and 10 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $243.3M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Abeona Therapeutics Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of ABEO: Q2 2021 compared with Q3 2021
MeasureQ2 2021Of which not filed for Q3 2021Q3 2021Change
Holders73160−12
Shares27.8M325.0K25.2M−2.27M (−8.2%)
Value$43.4M$507.0K$28.3M−$14.7M (−34.2%)

1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Abeona Therapeutics Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to ABEO in Q3 2021
InstitutionSharesValue% of portfolio
Franklin Resources Inc325,000$364.0K0.00%
ACT Capital Management, LLC278,000$311.0K0.16%
Renaissance Technologies LLC49,500$55.0K0.00%
Gsa Capital Partners LLP33,466$37.0K0.00%
Price T Rowe Associates Inc24,400$27.0K0.00%
Apollon Wealth Management, LLC10,000$11.0K0.00%

Sold out (18)

Institutions that held Abeona Therapeutics Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Not filed for Q3 2021 yet (1)

Institutions that held Abeona Therapeutics Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ABEO in Q2 2021 that haven't filed for Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
QS Investors, LLC325,000$507.0K